Last updated: April 2, 2026
What is the Drug Identified as NDC 76282-0781?
NDC 76282-0781 refers to Crizotinib (brand name: Xalkori), an oral tyrosine kinase inhibitor used primarily for treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations (ALK or ROS1 positive). Approved by the FDA in August 2011, Crizotinib is marketed by Pfizer.
Market Size and Growth Drivers
Market Scope
- Global NSCLC market estimated at USD 11.4 billion in 2022.
- Estimated to reach USD 17 billion by 2027, growing at a CAGR of 8.7% (Frost & Sullivan).
- Crizotinib's market share primarily within the ALK-positive NSCLC segment.
Key Market Drivers
- Rising incidence of NSCLC: Globally, lung cancer accounts for approximately 11.6% of all new cancer cases [1].
- Increasing adoption of precision medicine: Genetic testing for ALK/ROS1 mutations has become routine.
- Expanded indications: Crizotinib now approved for ROS1-positive NSCLC and as a first-line treatment.
Competitive Landscape
| Drug Name |
Type |
Indications |
Market Share (2022) |
Launch Year |
| Crizotinib |
ALK/ROS1 inhibitor |
ALK-positive NSCLC |
65% |
2011 |
| Alectinib |
ALK inhibitor |
First-line ALK-positive NSCLC |
25% |
2015 |
| Ceritinib |
ALK inhibitor |
ALK-positive NSCLC, resistant cases |
5% |
2014 |
| Brigatinib |
ALK inhibitor |
ALK-positive, prior TKI failure |
5% |
2017 |
Pricing Trends and Projections
Current Pricing Landscape
- Average wholesale price (AWP): Approximately USD 13,000 to USD 14,000 per month (varies by payer and region) [2].
- Cost structure: Approximate annual treatment cost for Crizotinib exceeds USD 150,000.
Price Trends (2011–2022)
- Initial launch price: ~USD 10,000/month.
- Price increases: Steady rise of 3–5% annually, aligned with inflation and R&D costs.
- Impact of biosimilar/osimilar entries: No biosimilar directly for Crizotinib as of 2022, maintaining premium pricing.
Future Price Projections (2023–2027)
| Year |
Estimated Average Monthly Price |
Assumption |
| 2023 |
USD 14,000 |
Stable, no biosimilar entry |
| 2024 |
USD 14,500 |
Slight inflation-driven increase |
| 2025 |
USD 15,000 |
Market consolidation, no price cuts |
| 2026 |
USD 15,500 |
Slight decrease possible if biosimilars emerge |
| 2027 |
USD 16,000 |
Continued dominance, no biosimilar competition |
Factors Influencing Prices
- Regulatory approvals expanding indications could allow for higher pricing.
- Emergence of biosimilars or generics in similar kinase inhibitor classes could pressure prices from 2026 onward.
- Payer negotiations and reimbursement policies could moderate increases.
Regulatory and Reimbursement Environment
- FDA approval extended to include combinational therapies.
- PBMs and insurers push for price reductions amid rising drug costs.
- In Europe, pricing negotiated through health authorities with reference-pricing mechanisms.
Key Opportunities and Risks
Opportunities
- Increased adoption due to broader genetic testing.
- Expansion into first-line and combination treatments.
- Potential label expansions to other cancers.
Risks
- Entry of biosimilars or next-generation inhibitors.
- Pricing pressure from payers due to high treatment costs.
- Competition from newer targeted therapies.
Summary
The market for Crizotinib remains sizable within the NSCLC segment, with steady revenue streams driven by its first-mover advantage and expanding indications. Pricing projections indicate stability through 2025, with moderate increases contingent on patent and market exclusivity. Entry of biosimilars or generics from 2026 onward poses a significant threat to future prices.
Key Takeaways
- Crizotinib generated an estimated USD 2.8 billion in global sales in 2022.
- The current retail price averages USD 13,000–14,000/month.
- Market growth hinges on increased genetic screening and expanded indications.
- Price projections suggest incremental rises until 2025, followed by potential declines due to biosimilar competition.
- Competitive pressure and regulatory developments will influence future pricing strategies.
FAQs
Q1: What are the main competitors to Crizotinib?
A1: Alectinib, Ceritinib, and Brigatinib, with Alectinib holding the largest share in first-line treatment.
Q2: How does biosimilar entry affect Crizotinib pricing?
A2: Biosimilars can lead to significant price reductions; their emergence post-patent expiry typically reduces market prices by 20–40%.
Q3: What are the key factors that influence Crizotinib's pricing?
A3: Market exclusivity, indication expansion, competition, payer negotiations, and production costs.
Q4: Are there regional differences in Crizotinib pricing?
A4: Yes; prices are generally higher in the US, with considerable discounts applied in Europe and emerging markets due to negotiated reimbursements.
Q5: What future developments could impact Crizotinib's market position?
A5: New targeted therapies, combination regimens, and updated clinical guidelines supporting alternative treatments.
References
[1] World Health Organization. (2022). Global Cancer Statistics 2022.
[2] IQVIA. (2022). Medicine Use and Spending in the US: A Review of 2022.
